Empirical Finance LLC Takes Position in Teleflex Incorporated (NYSE:TFX)

Empirical Finance LLC acquired a new stake in Teleflex Incorporated (NYSE:TFX – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 737 shares of the medical technology company’s stock, valued at approximately $242,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TFX. Wellington Management Group LLP lifted its holdings in Teleflex by 2.6% during the 3rd quarter. Wellington Management Group LLP now owns 3,263,400 shares of the medical technology company’s stock worth $1,228,833,000 after purchasing an additional 82,510 shares during the last quarter. American Century Companies Inc. lifted its holdings in Teleflex by 0.9% during the 3rd quarter. American Century Companies Inc. now owns 1,325,724 shares of the medical technology company’s stock worth $499,201,000 after purchasing an additional 12,194 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Teleflex by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 817,677 shares of the medical technology company’s stock worth $307,044,000 after purchasing an additional 23,959 shares during the last quarter. Franklin Resources Inc. raised its holdings in Teleflex by 2.1% in the 3rd quarter. Franklin Resources Inc. now owns 642,827 shares of the medical technology company’s stock valued at $242,057,000 after acquiring an additional 13,181 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in Teleflex by 12.1% in the 4th quarter. Bessemer Group Inc. now owns 573,704 shares of the medical technology company’s stock valued at $188,452,000 after acquiring an additional 62,059 shares in the last quarter. 91.86% of the stock is owned by institutional investors.

Shares of NYSE:TFX opened at $327.01 on Tuesday. The company has a market capitalization of $15.34 billion, a price-to-earnings ratio of 31.93, a P/E/G ratio of 1.85 and a beta of 1.06. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.10 and a quick ratio of 1.40. The business’s 50-day moving average is $337.45 and its 200-day moving average is $335.09. Teleflex Incorporated has a 1 year low of $289.00 and a 1 year high of $449.38.

Teleflex (NYSE:TFX – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The medical technology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.53 by $0.07. The company had revenue of $761.90 million for the quarter, compared to the consensus estimate of $749.60 million. Teleflex had a return on equity of 17.74% and a net margin of 17.28%. The firm’s revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the business earned $3.25 EPS. Analysts anticipate that Teleflex Incorporated will post 14 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 15th. Investors of record on Monday, March 7th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date was Friday, March 4th. Teleflex’s dividend payout ratio (DPR) is currently 13.28%.

Several equities analysts have weighed in on the company. Raymond James dropped their price objective on Teleflex from $391.00 to $370.00 and set an “outperform” rating for the company in a report on Wednesday, February 23rd. Morgan Stanley dropped their price objective on Teleflex from $383.00 to $378.00 and set an “equal weight” rating for the company in a report on Friday, February 25th. Zacks Investment Research lowered Teleflex from a “hold” rating to a “sell” rating and set a $373.00 price target on the stock. in a research note on Friday, April 1st. Needham & Company LLC decreased their price target on Teleflex from $425.00 to $400.00 and set a “buy” rating on the stock in a research note on Monday, January 31st. Finally, Truist Financial began coverage on Teleflex in a research report on Tuesday, April 12th. They set a “hold” rating and a $370.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $397.08.

Teleflex Company Profile (Get Rating)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Further Reading